Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29056645 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL4035833 | 0.93 | KEAP1 (0.50) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL2441195 | 0.86 | KEAP1 (0.43) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL15328845 | 0.86 | KEAP1 (0.43) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL2441151 | 0.86 | KEAP1 (0.43) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL3966764 | 0.86 | GNAI3 (0.59) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL508627 | 0.85 | ALOX15 (0.60) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3668361 | 0.84 | GNAI3 (0.62) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL855029 | 0.80 | GNAI3 (0.40) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL855030 | 0.80 | GNAI3 (0.40) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | LUPIN LIMITED (IN) | 2025-11-25 | — | — | US | disclosed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119255997-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119233976-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | LUPIN LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-4004002-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | Lupin Limited (IN) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174303-A | Macrocyclic compounds as STING agonists, methods and uses thereof | 印度鲁宾有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-2021331-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | KEAP1 1090/4885SMN1; SMN2 3226/4885GNAI3 1126/4885 |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | KEAP1 1984/4885SMN1; SMN2 1002/4885GNAI3 746/4885 |
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | STING1, CGAS, MAVS | KEAP1 813/4885SMN1; SMN2 2159/4885GNAI3 175/4885 |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | KEAP1 1090/4885SMN1; SMN2 3226/4885GNAI3 1126/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | KEAP1 1090/4885SMN1; SMN2 3226/4885GNAI3 1126/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | KEAP1 1090/4885SMN1; SMN2 3226/4885GNAI3 1126/4885 |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | STING1, CGAS, MAVS | KEAP1 813/4885SMN1; SMN2 2159/4885GNAI3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.